Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease
2007

PPAR Ligands and Airway Inflammation in Chronic Lung Disease

publication Evidence: moderate

Author Information

Author(s): Jane Elizabeth Ward, Tan Xiahui

Primary Institution: University of Melbourne

Hypothesis

PPARs may serve as additional therapeutic targets to control inflammation in chronic lung diseases like asthma.

Conclusion

PPAR ligands have shown potential in reducing airway inflammation and remodelling in chronic lung diseases.

Supporting Evidence

  • PPARs are involved in regulating inflammation in the lungs.
  • PPAR ligands can reduce the production of proinflammatory cytokines.
  • In murine models, PPAR ligands decreased airway hyperresponsiveness.

Takeaway

This study suggests that certain drugs can help reduce inflammation in the lungs, which is important for people with asthma.

Methodology

The review summarizes in vitro and in vivo evidence regarding the effects of PPAR ligands on airway inflammation.

Limitations

The review is based on existing studies and does not present new experimental data.

Digital Object Identifier (DOI)

10.1155/2007/14983

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication